Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Rh Blood Group

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study Group.

Haemophilia : the official journal of the World Federation of Hemophilia·2025

Same author

Hemophilia B Leyden: characteristics and natural history in the International Pediatric Network of Hemophilia Management Registry.

Journal of thrombosis and haemostasis : JTH·2025

Same author

BAY 81-8973 Demonstrates Long-Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study.

European journal of haematology·2024

Same author

Origin of pathogenic variant and mosaicism in families with a sporadic case of haemophilia B.

Haemophilia : the official journal of the World Federation of Hemophilia·2024

Same author

Prophylactic Treatment of Children with Hemophilia in Sweden.

Seminars in thrombosis and hemostasis·2024

Same author

Recombinant factor IX Fc for the treatment of hemophilia B.

European journal of haematology·2024

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Prophylactic therapy in haemophilia.

¹Departments of Paediatrics and Coagulation Disorders, Lund University, University Hospital, Malmö, Sweden. Rolf.Ljung@med.lu.se

|September 25, 2009

Summary

Prophylactic treatment for hemophilia is superior to on-demand treatment for reducing bleeds and improving quality of life. Early initiation (primary prophylaxis) is optimal, though secondary prophylaxis also offers benefits.

Area of Science:

Hematology
Internal Medicine

Background:

Hemophilia management has evolved from on-demand treatment to prophylactic regimens.
Clinical evidence supports the superiority of prophylactic treatment over on-demand therapy.

Purpose of the Study:

To review the evidence supporting prophylactic hemophilia treatment.
To compare prophylaxis with on-demand treatment regarding various outcomes.
To discuss health economics and future trends in hemophilia prophylaxis.

Main Methods:

Review of clinical experience, retrospective, and prospective studies.
Analysis of outcomes including bleeding events, arthropathy, and quality of life.
Consideration of health economic data and future treatment trends.

Related Experiment Videos

Last Updated: Jun 20, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Main Results:

Prophylactic treatment significantly reduces joint bleeds and life-threatening hemorrhages compared to on-demand treatment.
Both X-ray and MRI evaluations show better joint health with prophylaxis.
Quality of life is demonstrably improved with prophylactic regimens.

Conclusions:

Prophylactic hemophilia treatment, especially primary prophylaxis initiated early in life, is the gold standard.
Secondary prophylaxis provides benefits but is less cost-effective than primary prophylaxis.
Optimizing dose and interval for prophylaxis requires consideration of individual patient needs and healthcare resources.